





COLORECTAL CANCERS

Regional Approaches: Moving Beyond PRODIGE 7

Wim P. Ceelen, MD, PhD Professor of Surgical Oncology Ghent University, Belgium @WimCeelen

Advancing Innovative Therapies for Cancers That Invade the Peritoneum and the Pleura



No relevant financial relationships.

This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.





Cultural Linguistic Competency (CLC) & Implicit Bias (IB)

STATE LAW:

The California legislature has passed <u>Assembly Bill (AB) 1195</u>, which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed <u>AB 241</u>, which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.

EXEMPTION:

Business and Professions Code 2190.1 exempts activities which are dedicated solely to research or other issues that do not contain a direct patient care component.

This presentation is dedicated solely to research or other issues that do not contain a direct patient care component.






PRODIGE 7 – what where the results?

Sex Male Primary tumour side Right colon Other Positive lymph nodes (primary tumour) No	35/65 44/68 28/51 51/82	44/67 — 36/65 33/51 47/81		0-72 (0-46-1-12) 1-31 (0-84-2-03) 0-89 (0-53-1-46)	0.06 0.65
^r emale Primary tumour side Right colon Dther Positive lymph nodes (primary tumour) No	44/68 28/51 51/82	36/65 33/51		1·31 (0·84-2·03) 0·89 (0·53-1·46)	0.65
Primary tumour side Right colon Other Positive lymph nodes (primary tumour) No	28/51 51/82	33/51	 	0.89 (0.53-1.46)	0.65
Right colon Other Positive lymph nodes (primary tumour) No	51/82		_ _		0.65
Other Positive lymph nodes (primary tumour) No	51/82				
Positive lymph nodes (primary tumour) No		47/81			
No				1.03 (0.69-1.53)	
					0.39
	18/40	18/30		0.72 (0.38-1.39)	
/es	54/84	58/95		1.01 (0.69-1.46)	
Previous chemotherapy					0.75
First line	57/99	52/89		1.02 (0.70-1.48)	
Second or third line	22/34	28/43		0.91 (0.52-1.59)	
Preoperative nutrition					0.21
No	14/21	14/24		1.50 (0.71-3.14)	
/es	63/109	65/107		0.88 (0.62-1.25)	
Preoperative systemic chemotherapy					0.32
No	58/103	63/110		0.99 (0.69-1.41)	
/es	21/30	17/ 22	-	0.68 (0.36-1.29)	
Postoperative systemic chemotherapy					0.20
No	69/117	73/114		0.89 (0.64-1.24)	
/es	10/16	7/ 18		 1.73 (0.66–4.55) 	
Preoperative and postoperative systemic chemotherapy					0.19
No	37/53	26/45		1.25 (0.75-2.06)	
/es	42/80	54/ 87		0-81 (0-54-1-21)	
201					0.14
<11	34/75	36/77		1.00 (0.63-1.60)	
11-15	11/18	23/28	12	0.44 (0.21-0.90)	
-15	34/40	21/27		1.11 (0.64-1.92)	
Resection					0.94
Complete macroscopic cytoreduction	70/119	72/121		0.97 (0.70-1.35)	
Complete macroscopic residual disease <1 mm	9/14	8/11		0.93 (0.36-2.41)	
Overall	79/133	80/132	-	0.97 (0.71-1.33)	

Favours cytoreductive Favours cytoreductive surgery plus HIPEC surgery

Primary endpoint (OS)

Quénet Lancet Oncol 2021



OVHIPEC-1 trial (Van Driel, NEJM 2018)


Variable	PRODIGE 7	OVHIPEC-1
Primary endpoint	OS	PFS
Median follow-up	68 months	56 months
Response rate	OX single agent: 12-24%	Pt: 60-80%
Pretreatment systemic Tx	44% OX	100% Carboplatin-Paclitaxel
Complete debulking	~ 90%	~ 68%
Perfusate	Dextrose G5%	NaCl 0.9%
Duration	30 min	90 min
Perfusion temperature	43°C	40°C

Which endpoint for a local therapy?


	Advantage	Disadvantage
Overall survival	Relevant for patients Easily measured	Confounded by intervening therapies
PFS, DFS	More impacted by locoregional therapies	Cannot be precisely measured Not always a valid surrogate for OS









CMS 4 type: resistant to Oxaliplatin






Ubink Br J Surg 2019




	Physioneal 40	Dextrose 5%	NaCl 0.9%	Icodextrin 4%	Plasma
Glucose %	1.36%	5%	-	-	variable
Osmolarity (mOsm/L)	344	252	308	278	308
рН	7.4	4.3	5.4	5	7.4
Na (mEq/L)	132	-	154	133	140
Cl (mEq/L)	95	-	154	96	100
Lactate (mmol/L)	15	-	-	40	1





Huber Sem Cancer Biol 2017


Potential adverse effects of Glucose



Importance of exposure time for cancer cell kill







30min 60min 90min

Mitomycin-C 35mg/m2




0.0

Ctrl


Colorectal PDX expanded organoids


Roy Int J Pharm 2017




Colorectal PDX expanded organoids

In vitro cell lines







What explains the lack of effect in PRODIGE 7?

- General limitation of HIPEC: data on thermal enhancement and immune effects of mild hyperthermia limited and conflicting
- Intrinsic resistance to OX (CMS 4 type)
- Single, short duration
- Use of Dextose 5%








- Switch to Mitomycine C, 90 min, 40°C, in NACI 0.9% or PD solution
- Back to the drawing board: in vitro and animal studies





HIPECT4 trial

Results:



pT4 subgroup



Arjona-Sanchez Alvaro

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.



- Personalized approach: chemosensitivity testing (organoids, tumor fragments, circulating biomarkers,...)
- Prolonged IP delivery
 - \circ Nanoparticles
 - \circ IP hydrogels
- IP immune modulation







Prolonged release IPDD platforms


Table 2. The advantages and disadvantages of intraperitoneally administered drug delivery systems.

Intraperitoneal Drug Delivery Systems (DDS)	Type of DDS	Drug
Microparticulates	PLGA microparticles	Paclitaxel [77]
	Polyphosphoester microspheres (Paclimer)	Paclitaxel [78]
	Poly(ethylene glycol), poly(sebacic acid) microspheres	Paclitaxel [79]
	PLGA microspheres	[80]
Nanoparticulates	PLGA nanospheres	[80]
	Polylactic acid block – hyperbranched polyglycerol (PLA-HPG) copolymer-based bioadhesive nanoparticles	Epothilone B [81]
	Nanoparticulate powder, Nanotax	Paclitaxel [82,83]
Injectable gel-based	Pluronic F127-Tween 80 thermosensitive mixed micelle gel	Docetaxel [84]
systems	Hyaluronic acid (HA) gel with micrometer scale drug precipitates	Paclitaxel [85]
	Hyaluronic acid (HA) gel with drug nanoparticle	Carboplatin [86]
	Hyaluronic acid (HA) gel with drug nanocrystals	Paclitaxel [87]
	Poly(ethylene glycol)-poly(epsilon-caprolactone)- poly (ethylene glycol) (PEG- PCL-PEG thermosensitive hydrogel with drug nanoparticles	Honokiol [88]
	Water-soluble chitosan derivative, egg phosphatidylcholine (ePC), fatty acid chloride-based injectable blend	Paclitaxel [95]
	Water soluble chitosan derivative, egg phosphatidylcholine (ePC), fatty acid chloride-based injectable blend (PoLigel)	Docetaxel [96–99]
Implants	Chitosan, egg phosphatidylcholine hydrogel film with polylactide-drug nanoparticles	Paclitaxel [89–93]
	Poly-L-lactic acid (PLLA) injection molded microdevices	Cisplatin [100]






Thermosensitive hydrogel





In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment



Overview of Therapeutic Strategies Aimed at Reengineering the Tumor Microenvironment of Colorectal Peritoneal Metastases




Figure 2. Abbreviations: CAR-T, chimeric antigen receptor T cell; ECM, extracellular matrix; TGF-β, transforming growth factor-β; TLR, Toll-like receptor.

Conclusions

- Treatment of colorectal PM remains a challenge
- Recent RCTs show no benefit of HIPEC with OX
- Areas of potential progress:
 - Prolonged/metronomic delivery: gels, depots, biomaterials
 - Engineering of the TME; immune modulation
 - Personalized therapy: drug sensitivity testing

